Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01340885 · ClinicalTrials.gov registry record · Phase 4
Cognitive Decline in Non-demented PD
A Phase 4 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT01340885: Completed Phase 4 study, sponsored by Oregon Health and Science University.
NCT01340885 is a Phase 4 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 9 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01340885, a Phase 4 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).
Interventions
- OTHER Placebo
- DRUG Strattera
- DRUG Exelon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
What the finished NCT01340885 record still lists
NCT01340885 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01340885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01340885 about?
NCT01340885 is a clinical study titled "Cognitive Decline in Non-demented PD". The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).
What is the current status of trial NCT01340885?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2011-01. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01340885?
The interventions under investigation include: Placebo (OTHER), Strattera (DRUG), Exelon (DRUG).
Who is sponsoring clinical trial NCT01340885?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01340885's enrollment target sits among peer trials
9 1968th of 2000 higher than 29 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia